Drug Topics

JUNE 6, 2023

With the rise of prescription digital therapeutics, pharmacists will need to prepare to manage the new paradigms of care.

226

226

Pharmacy Times

JUNE 9, 2023

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

FDA 182

FDA 182

Fierce Healthcare

JUNE 9, 2023

Emerging Alzheimer’s disease medications come with high price tags, but researchers with the University of Chicago calculate that in the long run, it’s much less costly to cover these therapies for | Emerging Alzheimer’s medications come with high price tags, but researchers with the University of Chicago calculate that in the long run, it’s much less costly to cover these therapies for Medicare beneficiaries.

145

145

Fierce Pharma

JUNE 9, 2023

After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing. | After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing.

FDA 144

FDA 144

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

JUNE 8, 2023

Which masks (if any) serve as the best protection against wildfire smoke, and what do experts say about home appliances like air conditioners?

186

186

Pharmacy Times

JUNE 5, 2023

It’s imperative to redefine the future of pharmacy to help ensure a robust pipeline of future pharmacists and create a culture that helps ensure pharmacists live their purpose and passion.

Community Pharmacies 172

Community Pharmacies 172

Fierce Healthcare

JUNE 6, 2023

Advancements around large language models and generative AI in healthcare are ramping up quickly and it's challenging to keep up with the evolving news. | Carbon Health debuted hands-free charting — an AI-enabled notes assistant — in its proprietary EHR across each of its clinics and providers while Tempus rolled out an AI-enabled clinical assistant for oncologists.

140

140

Drug Topics

JUNE 7, 2023

The median annual cost for new oncology medicines launched in 2022 was $260,000, up from $63,534 10 years ago, an IQVIA report finds.

185

185

Pharmacy Times

JUNE 8, 2023

Neuromyelitis optica spectrum disorder is an autoimmune disease characterized by severe attacks of optic neuritis and/or myelitis, leading to possible visual loss, paralysis, cognitive impairment, sensory deficits, bladder dysfunction, and even mortality.

139

139

STAT

JUNE 7, 2023

BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. Robert Califf, the Food and Drug Administration chief, walked on stage Wednesday and told a crowd of biotech leaders that drug costs needed fixing. “We don’t agree,” said Califf, referring to a conversation he had backstage with Ted Love , the new chair of the Biotechnology Innovation Organization.

Insurance 144

Insurance FDA 144

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

JUNE 9, 2023

The Federal Trade Commission is building out its deep dive into the pharmacy benefit management industry yet again. | The Federal Trade Commission is building out its deep dive into the pharmacy benefit management industry yet again.

139

139

Drug Topics

JUNE 7, 2023

The role of pharmacy benefit managers in the health care space is being scrutinized more than ever before.

184

184

Pharmacy Times

JUNE 3, 2023

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

Immunization 132

Immunization 132

STAT

JUNE 7, 2023

An unusually early and ferocious outbreak of forest fires across Canada has sent unprecedented amounts of smoke pollution to regions of the eastern United States unaccustomed to such hazards. Three years after the onset of the Covid-19 pandemic, the ensuing air pollution has once again put respiratory health at the forefront of many North Americans’ minds.

142

142

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

JUNE 5, 2023

The roughly half of American smartphone users with iPhones will notice new health and pri | Apple brings its Health app to the iPad while offering new vision and mental health features to its suite of devices.

138

138

Drug Topics

JUNE 6, 2023

According to a spokesperson, the company is prepared to take the lawsuit to the Supreme Court.

187

187

Fierce Pharma

JUNE 4, 2023

AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. | AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. Now, the companies are positioning the HER2 antibody-drug conjugate for expansion into other tumor types with data that researchers view as very compelling.

133

133

STAT

JUNE 6, 2023

Is the pandemic over ? On the one hand, Covid-19 is clearly still with us. In the U.S., over the past month there was a weekly average of 557 deaths , though the numbers are dropping sharply, from 849 four weeks ago to 208 last week. On the other, for those who are not vulnerable or immune compromised, most facets of life have returned to normal, thanks to high levels of immunity from vaccines, boosters, and past infections.

Hospitals 141

Hospitals Immunization Vaccines 141

Fierce Healthcare

JUNE 6, 2023

Mayo Clinic is collaborating with Google Cloud to supercharge search tools with generative AI. | Mayo Clinic is collaborating with Google Cloud to supercharge search tools with generative AI. The health system aims to use the buzzy new technology to make it easier for doctors to get access to relevant medical notes, research papers or clinical guidelines.

Mayo Clinic 135

Mayo Clinic 135

Drug Topics

JUNE 6, 2023

A research article outlines the future of artificial intelligence in health care.

187

187

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). | Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. At the BIO International Convention, Biogen CEO Chris Viehbacher registered severe criticism of the IRA and said his company was considering filing its own lawsuit.

131

131

STAT

JUNE 9, 2023

Heart monitoring company iRhythm is in hot water with the Food and Drug Administration, which issued a stern warning letter to the device maker this week for marketing its product for “high risk” patients and changing its algorithm without seeking the FDA’s permission. The letter highlights FDA’s growing scrutiny of digital health and patient monitoring tools — as well as the grave impacts even small device glitches can have on patients.

FDA 133

FDA 133

Fierce Healthcare

JUNE 8, 2023

The Centers for Medicare and Medicaid Services aims to advance value-based primary care, especially in rural areas and among underserved populations, with a new pilot project. | The Centers for Medicare and Medicaid Services aims to advance value-based primary care, especially in rural areas and among underserved populations, with a new pilot project.

133

133

Drug Topics

JUNE 7, 2023

Air quality in New York City was the worst in the world on Tuesday morning.

185

185

Pharmacy Times

JUNE 9, 2023

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

Community Pharmacies 130

Community Pharmacies 130

Fierce Pharma

JUNE 3, 2023

The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and fast-growing members of the group, was defeated by immune checkpoint inhibitor. | The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and fast-growing members of the group, was defeated by immune checkpoint inhibitor in classical Hodgkin lymphoma.

Immunization 130

Immunization 130

Fierce Healthcare

JUNE 6, 2023

Despite physician and advanced practice provider productivity continuing its post-pandemic recovery, compensation gains are being outstripped by the most severe inflationary growth in decades, acco | Despite physician and advanced practice provider productivity continuing its post-pandemic recovery, compensation gains are being outstripped by the most severe inflationary growth in decades, according to a new report.

129

129

Drug Topics

JUNE 5, 2023

Patients were more likely to require ICU admission.

Hospitals 187

Hospitals 187

Pharmacy Times

JUNE 6, 2023

Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.

123

123

Fierce Pharma

JUNE 7, 2023

As Alzheimer's disease partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. | As Alzheimer's partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. On Wednesday, that vision came into better focus as the FDA released a document showing how the agency views the drug.

Documentation 129

Documentation FDA 129

Fierce Healthcare

JUNE 5, 2023

The home health bidding wars are heating up as UnitedHealth Group's Optum unit is making a big play for home health and hospice firm Amedisys. |.Just one month ago, Amedisys agreed to be bought by another healthcare company, Option Care Health, a provider of post-acute care and infusion services.

126

126

STAT

JUNE 4, 2023

CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday. The drug, called Elahere, is made by the biotech company Immunogen. It was granted conditional approval in the U.S. last November based on preliminary evidence showing it shrank tumors.

Chemotherapy 123

Chemotherapy 123

Pharmacy Times

JUNE 3, 2023

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

123

123

Fierce Pharma

JUNE 7, 2023

The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. | The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. On Wednesday, the government unveiled a two-year pilot program that will allow Novo Nordisk’s Wegovy to be given to more overweight participants, even though the treatment has yet to be launched there.

123

123